메뉴 건너뛰기




Volumn 11, Issue 9, 2013, Pages 1627-1639

Pharmacogenomics in cardiovascular disease: Focus on aspirin and ADP receptor antagonists

Author keywords

ADP receptor antagonists; Aspirin; Cardiovascular disease; Clopidogrel; Pharmacogenomics

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; TICAGRELOR;

EID: 84883768685     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12318     Document Type: Article
Times cited : (26)

References (102)
  • 1
    • 84870040186 scopus 로고    scopus 로고
    • Platelet function testing in atherothrombotic disease
    • Grove EL, Storey RF, Wurtz M. Platelet function testing in atherothrombotic disease. Curr Pharm Des 2012; 18: 5379-91.
    • (2012) Curr Pharm Des , vol.18 , pp. 5379-5391
    • Grove, E.L.1    Storey, R.F.2    Wurtz, M.3
  • 2
    • 84857544534 scopus 로고    scopus 로고
    • Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?
    • Cattaneo M. Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution? J Thromb Haemost 2012; 10: 327-36.
    • (2012) J Thromb Haemost , vol.10 , pp. 327-336
    • Cattaneo, M.1
  • 3
    • 84870047461 scopus 로고    scopus 로고
    • Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance
    • Wurtz M, Grove EL. Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. Curr Pharm Des 2012; 18: 5344-61.
    • (2012) Curr Pharm Des , vol.18 , pp. 5344-5361
    • Wurtz, M.1    Grove, E.L.2
  • 6
    • 34248352504 scopus 로고    scopus 로고
    • Aspirin dose for the prevention of cardiovascular disease: a systematic review
    • Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007; 297: 2018-24.
    • (2007) JAMA , vol.297 , pp. 2018-2024
    • Campbell, C.L.1    Smyth, S.2    Montalescot, G.3    Steinhubl, S.R.4
  • 8
    • 73149119363 scopus 로고    scopus 로고
    • Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite
    • Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92-9.
    • (2010) Drug Metab Dispos , vol.38 , pp. 92-99
    • Kazui, M.1    Nishiya, Y.2    Ishizuka, T.3    Hagihara, K.4    Farid, N.A.5    Okazaki, O.6    Ikeda, T.7    Kurihara, A.8
  • 11
  • 12
    • 0033586430 scopus 로고    scopus 로고
    • Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation
    • Undas A, Sanak M, Musial J, Szczeklik A. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 1999; 353: 982-3.
    • (1999) Lancet , vol.353 , pp. 982-983
    • Undas, A.1    Sanak, M.2    Musial, J.3    Szczeklik, A.4
  • 13
    • 0042735242 scopus 로고    scopus 로고
    • Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms
    • Macchi L, Christiaens L, Brabant S, Sorel N, Ragot S, Allal J, Mauco G, Brizard A. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 2003; 42: 1115-19.
    • (2003) J Am Coll Cardiol , vol.42 , pp. 1115-1119
    • Macchi, L.1    Christiaens, L.2    Brabant, S.3    Sorel, N.4    Ragot, S.5    Allal, J.6    Mauco, G.7    Brizard, A.8
  • 15
    • 47249143688 scopus 로고    scopus 로고
    • Pharmacogenetics of aspirin resistance: a comprehensive systematic review
    • Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008; 66: 222-32.
    • (2008) Br J Clin Pharmacol , vol.66 , pp. 222-232
    • Goodman, T.1    Ferro, A.2    Sharma, P.3
  • 16
    • 0037256309 scopus 로고    scopus 로고
    • Genetic variation in cyclooxygenase 1: effects on response to aspirin
    • Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003; 73: 122-30.
    • (2003) Clin Pharmacol Ther , vol.73 , pp. 122-130
    • Halushka, M.K.1    Walker, L.P.2    Halushka, P.V.3
  • 18
    • 12844269195 scopus 로고    scopus 로고
    • Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?
    • Gonzalez-Conejero R, Rivera J, Corral J, Acuna C, Guerrero JA, Vicente V. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005; 36: 276-80.
    • (2005) Stroke , vol.36 , pp. 276-280
    • Gonzalez-Conejero, R.1    Rivera, J.2    Corral, J.3    Acuna, C.4    Guerrero, J.A.5    Vicente, V.6
  • 20
    • 0032721596 scopus 로고    scopus 로고
    • Mutations of the platelet thromboxane A2 (TXA2) receptor in patients characterized by the absence of TXA2-induced platelet aggregation despite normal TXA2 binding activity
    • Higuchi W, Fuse I, Hattori A, Aizawa Y. Mutations of the platelet thromboxane A2 (TXA2) receptor in patients characterized by the absence of TXA2-induced platelet aggregation despite normal TXA2 binding activity. Thromb Haemost 1999; 82: 1528-31.
    • (1999) Thromb Haemost , vol.82 , pp. 1528-1531
    • Higuchi, W.1    Fuse, I.2    Hattori, A.3    Aizawa, Y.4
  • 22
    • 33748607448 scopus 로고    scopus 로고
    • Identification of functional polymorphisms of the thromboxane A2 receptor gene in healthy volunteers
    • Fontana P, Gandrille S, Remones V, Dupont A, Reny JL, Aiach M, Gaussem P. Identification of functional polymorphisms of the thromboxane A2 receptor gene in healthy volunteers. Thromb Haemost 2006; 96: 356-60.
    • (2006) Thromb Haemost , vol.96 , pp. 356-360
    • Fontana, P.1    Gandrille, S.2    Remones, V.3    Dupont, A.4    Reny, J.L.5    Aiach, M.6    Gaussem, P.7
  • 25
    • 33845490833 scopus 로고    scopus 로고
    • Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel
    • Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 2007; 119: 355-60.
    • (2007) Thromb Res , vol.119 , pp. 355-360
    • Lev, E.I.1    Patel, R.T.2    Guthikonda, S.3    Lopez, D.4    Bray, P.F.5    Kleiman, N.S.6
  • 27
    • 60849137489 scopus 로고    scopus 로고
    • Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease
    • Kunicki TJ, Williams SA, Nugent DJ, Harrison P, Segal HC, Syed A, Rothwell PM. Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thromb Haemost 2009; 101: 123-33.
    • (2009) Thromb Haemost , vol.101 , pp. 123-133
    • Kunicki, T.J.1    Williams, S.A.2    Nugent, D.J.3    Harrison, P.4    Segal, H.C.5    Syed, A.6    Rothwell, P.M.7
  • 28
    • 38849189504 scopus 로고    scopus 로고
    • Association of the platelet membrane glycoprotein I a C807T gene polymorphism with aspirin resistance
    • Su G, Wang Z, Ding Y. Association of the platelet membrane glycoprotein I a C807T gene polymorphism with aspirin resistance. J Huazhong Univ Sci Technolog Med Sci 2007; 27: 664-7.
    • (2007) J Huazhong Univ Sci Technolog Med Sci , vol.27 , pp. 664-667
    • Su, G.1    Wang, Z.2    Ding, Y.3
  • 29
    • 33646235405 scopus 로고    scopus 로고
    • Detection of functional differences between different platelet membrane glycoprotein Ibalpha variable number tandem repeat and Kozak genotypes as shown by the PFA-100 system
    • Douglas H, Davies GJ, Michaelides K, Gorog DA, Timlin H, Ahmed N, Tuddenham EG. Detection of functional differences between different platelet membrane glycoprotein Ibalpha variable number tandem repeat and Kozak genotypes as shown by the PFA-100 system. Heart 2006; 92: 676-8.
    • (2006) Heart , vol.92 , pp. 676-678
    • Douglas, H.1    Davies, G.J.2    Michaelides, K.3    Gorog, D.A.4    Timlin, H.5    Ahmed, N.6    Tuddenham, E.G.7
  • 33
    • 0024320643 scopus 로고
    • Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels
    • Bjornsson TD, Schneider DE, Berger H Jr. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther 1989; 250: 154-61.
    • (1989) J Pharmacol Exp Ther , vol.250 , pp. 154-161
    • Bjornsson, T.D.1    Schneider, D.E.2    Berger Jr., H.3
  • 35
    • 0037422559 scopus 로고    scopus 로고
    • Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism
    • Undas A, Sydor WJ, Brummel K, Musial J, Mann KG, Szczeklik A. Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation 2003; 107: 17-20.
    • (2003) Circulation , vol.107 , pp. 17-20
    • Undas, A.1    Sydor, W.J.2    Brummel, K.3    Musial, J.4    Mann, K.G.5    Szczeklik, A.6
  • 38
    • 77958105401 scopus 로고    scopus 로고
    • Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis
    • Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376: 1312-19.
    • (2010) Lancet , vol.376 , pp. 1312-1319
    • Mega, J.L.1    Close, S.L.2    Wiviott, S.D.3    Shen, L.4    Walker, J.R.5    Simon, T.6    Antman, E.M.7    Braunwald, E.8    Sabatine, M.S.9
  • 41
    • 77958100874 scopus 로고    scopus 로고
    • Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor vs. clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
    • Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, Becker RC. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor vs. clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-8.
    • (2010) Lancet , vol.376 , pp. 1320-1328
    • Wallentin, L.1    James, S.2    Storey, R.F.3    Armstrong, M.4    Barratt, B.J.5    Horrow, J.6    Husted, S.7    Katus, H.8    Steg, P.G.9    Shah, S.H.10    Becker, R.C.11
  • 43
    • 84874550138 scopus 로고    scopus 로고
    • Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function
    • Frelinger AL III, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 2013; 61: 872-9.
    • (2013) J Am Coll Cardiol , vol.61 , pp. 872-879
    • Frelinger III, A.L.1    Bhatt, D.L.2    Lee, R.D.3    Mulford, D.J.4    Wu, J.5    Nudurupati, S.6    Nigam, A.7    Lampa, M.8    Brooks, J.K.9    Barnard, M.R.10    Michelson, A.D.11
  • 45
    • 79961034838 scopus 로고    scopus 로고
    • The genetic basis of platelet responsiveness to clopidogrel. A critical review of the literature
    • Fefer P, Matetzky S. The genetic basis of platelet responsiveness to clopidogrel. A critical review of the literature. Thromb Haemost 2011; 106: 203-10.
    • (2011) Thromb Haemost , vol.106 , pp. 203-210
    • Fefer, P.1    Matetzky, S.2
  • 47
    • 67649645191 scopus 로고    scopus 로고
    • Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
    • Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, Man M, Siegbahn A, Walker J, Wallentin L, Winters KJ, Close SL. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 2009; 30: 1744-52.
    • (2009) Eur Heart J , vol.30 , pp. 1744-1752
    • Varenhorst, C.1    James, S.2    Erlinge, D.3    Brandt, J.T.4    Braun, O.O.5    Man, M.6    Siegbahn, A.7    Walker, J.8    Wallentin, L.9    Winters, K.J.10    Close, S.L.11
  • 50
    • 33749339075 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
    • Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-7.
    • (2006) Blood , vol.108 , pp. 2244-2247
    • Hulot, J.S.1    Bura, A.2    Villard, E.3    Azizi, M.4    Remones, V.5    Goyenvalle, C.6    Aiach, M.7    Lechat, P.8    Gaussem, P.9
  • 52
    • 43049179414 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
    • Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Buttner HJ, Neumann FJ. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51: 1925-34.
    • (2008) J Am Coll Cardiol , vol.51 , pp. 1925-1934
    • Trenk, D.1    Hochholzer, W.2    Fromm, M.F.3    Chialda, L.E.4    Pahl, A.5    Valina, C.M.6    Stratz, C.7    Schmiebusch, P.8    Bestehorn, H.P.9    Buttner, H.J.10    Neumann, F.J.11
  • 55
    • 80052285369 scopus 로고    scopus 로고
    • Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome
    • Cuisset T, Quilici J, Cohen W, Fourcade L, Saut N, Pankert M, Gaborit B, Carrieri P, Morange PE, Bonnet JL, Alessi MC. Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome. Am J Cardiol 2011; 108: 760-5.
    • (2011) Am J Cardiol , vol.108 , pp. 760-765
    • Cuisset, T.1    Quilici, J.2    Cohen, W.3    Fourcade, L.4    Saut, N.5    Pankert, M.6    Gaborit, B.7    Carrieri, P.8    Morange, P.E.9    Bonnet, J.L.10    Alessi, M.C.11
  • 56
    • 84883803050 scopus 로고    scopus 로고
    • Food and Drug Administration. FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug., Accessed June 7, 2013.
    • Food and Drug Administration. FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm. Accessed June 7, 2013.
    • (2010)
  • 58
    • 77953896604 scopus 로고    scopus 로고
    • Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis
    • Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthelemy O, Cayla G, Beygui F, Montalescot G. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010; 56: 134-43.
    • (2010) J Am Coll Cardiol , vol.56 , pp. 134-143
    • Hulot, J.S.1    Collet, J.P.2    Silvain, J.3    Pena, A.4    Bellemain-Appaix, A.5    Barthelemy, O.6    Cayla, G.7    Beygui, F.8    Montalescot, G.9
  • 64
    • 84555195438 scopus 로고    scopus 로고
    • CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis
    • Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011; 306: 2704-14.
    • (2011) JAMA , vol.306 , pp. 2704-2714
    • Holmes, M.V.1    Perel, P.2    Shah, T.3    Hingorani, A.D.4    Casas, J.P.5
  • 65
    • 84858999257 scopus 로고    scopus 로고
    • Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
    • Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011; 343: d4588.
    • (2011) BMJ , vol.343
    • Bauer, T.1    Bouman, H.J.2    van Werkum, J.W.3    Ford, N.F.4    ten Berg, J.M.5    Taubert, D.6
  • 66
    • 84155167902 scopus 로고    scopus 로고
    • Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel
    • Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomas M, Masia R, Marrugat J, Brugada R, Elosua R. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 2012; 98: 100-8.
    • (2012) Heart , vol.98 , pp. 100-108
    • Zabalza, M.1    Subirana, I.2    Sala, J.3    Lluis-Ganella, C.4    Lucas, G.5    Tomas, M.6    Masia, R.7    Marrugat, J.8    Brugada, R.9    Elosua, R.10
  • 67
    • 30344457586 scopus 로고    scopus 로고
    • A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
    • Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79: 103-13.
    • (2006) Clin Pharmacol Ther , vol.79 , pp. 103-113
    • Sim, S.C.1    Risinger, C.2    Dahl, M.L.3    Aklillu, E.4    Christensen, M.5    Bertilsson, L.6    Ingelman-Sundberg, M.7
  • 68
    • 67949120411 scopus 로고    scopus 로고
    • The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome
    • Frere C, Cuisset T, Gaborit B, Alessi MC, Hulot JS. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J Thromb Haemost 2009; 7: 1409-11.
    • (2009) J Thromb Haemost , vol.7 , pp. 1409-1411
    • Frere, C.1    Cuisset, T.2    Gaborit, B.3    Alessi, M.C.4    Hulot, J.S.5
  • 69
    • 76349098199 scopus 로고    scopus 로고
    • Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement
    • Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schomig A, von Beckerath N, Kastrati A. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121: 512-18.
    • (2010) Circulation , vol.121 , pp. 512-518
    • Sibbing, D.1    Koch, W.2    Gebhard, D.3    Schuster, T.4    Braun, S.5    Stegherr, J.6    Morath, T.7    Schomig, A.8    von Beckerath, N.9    Kastrati, A.10
  • 71
    • 84876148773 scopus 로고    scopus 로고
    • Besides CYP2C19, PON1 genetic variant influences post-clopidogrel platelet reactivity in Chinese patients
    • Wu H, Qian J, Xu J, Sun A, Sun W, Wang Q, Ge J. Besides CYP2C19, PON1 genetic variant influences post-clopidogrel platelet reactivity in Chinese patients. Int J Cardiol 2013; 165: 204-6.
    • (2013) Int J Cardiol , vol.165 , pp. 204-206
    • Wu, H.1    Qian, J.2    Xu, J.3    Sun, A.4    Sun, W.5    Wang, Q.6    Ge, J.7
  • 73
    • 82955240702 scopus 로고    scopus 로고
    • CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients
    • Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, Scott SA, Montalescot G. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv 2011; 4: 422-8.
    • (2011) Circ Cardiovasc Interv , vol.4 , pp. 422-428
    • Hulot, J.S.1    Collet, J.P.2    Cayla, G.3    Silvain, J.4    Allanic, F.5    Bellemain-Appaix, A.6    Scott, S.A.7    Montalescot, G.8
  • 75
    • 80052790906 scopus 로고    scopus 로고
    • Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement
    • Trenk D, Hochholzer W, Fromm MF, Zolk O, Valina CM, Stratz C, Neumann FJ. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet 2011; 4: 429-36.
    • (2011) Circ Cardiovasc Genet , vol.4 , pp. 429-436
    • Trenk, D.1    Hochholzer, W.2    Fromm, M.F.3    Zolk, O.4    Valina, C.M.5    Stratz, C.6    Neumann, F.J.7
  • 76
    • 84860811327 scopus 로고    scopus 로고
    • Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the clopidogrel in the unstable angina to prevent recurrent events trial and the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events
    • Pare G, Ross S, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Fox KA, Eikelboom JW. Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the clopidogrel in the unstable angina to prevent recurrent events trial and the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Circ Cardiovasc Genet 2012; 5: 250-6.
    • (2012) Circ Cardiovasc Genet , vol.5 , pp. 250-256
    • Pare, G.1    Ross, S.2    Mehta, S.R.3    Yusuf, S.4    Anand, S.S.5    Connolly, S.J.6    Fox, K.A.7    Eikelboom, J.W.8
  • 79
    • 0042859862 scopus 로고    scopus 로고
    • Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects
    • Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989-95.
    • (2003) Circulation , vol.108 , pp. 989-995
    • Fontana, P.1    Dupont, A.2    Gandrille, S.3    Bachelot-Loza, C.4    Reny, J.L.5    Aiach, M.6    Gaussem, P.7
  • 80
    • 0346365089 scopus 로고    scopus 로고
    • P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study
    • Fontana P, Gaussem P, Aiach M, Fiessinger JN, Emmerich J, Reny JL. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation 2003; 108: 2971-3.
    • (2003) Circulation , vol.108 , pp. 2971-2973
    • Fontana, P.1    Gaussem, P.2    Aiach, M.3    Fiessinger, J.N.4    Emmerich, J.5    Reny, J.L.6
  • 81
    • 63149100441 scopus 로고    scopus 로고
    • Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene
    • Staritz P, Kurz K, Stoll M, Giannitsis E, Katus HA, Ivandic BT. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. Int J Cardiol 2009; 133: 341-5.
    • (2009) Int J Cardiol , vol.133 , pp. 341-345
    • Staritz, P.1    Kurz, K.2    Stoll, M.3    Giannitsis, E.4    Katus, H.A.5    Ivandic, B.T.6
  • 83
    • 33947520739 scopus 로고    scopus 로고
    • Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome
    • Cuisset T, Frere C, Quilici J, Morange PE, Saut N, Romero-Barra M, Camoin L, Lambert M, Juhan-Vague I, Bonnet JL, Alessi MC. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. Thromb Haemost 2007; 97: 212-17.
    • (2007) Thromb Haemost , vol.97 , pp. 212-217
    • Cuisset, T.1    Frere, C.2    Quilici, J.3    Morange, P.E.4    Saut, N.5    Romero-Barra, M.6    Camoin, L.7    Lambert, M.8    Juhan-Vague, I.9    Bonnet, J.L.10    Alessi, M.C.11
  • 91
    • 84861494090 scopus 로고    scopus 로고
    • Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study
    • Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL, Schork NJ, Teirstein PS, Topol EJ. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol 2012; 59: 1928-37.
    • (2012) J Am Coll Cardiol , vol.59 , pp. 1928-1937
    • Price, M.J.1    Murray, S.S.2    Angiolillo, D.J.3    Lillie, E.4    Smith, E.N.5    Tisch, R.L.6    Schork, N.J.7    Teirstein, P.S.8    Topol, E.J.9
  • 94
    • 79955093619 scopus 로고    scopus 로고
    • Platelet inhibition by adjunctive cilostazol vs. high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype
    • Kim IS, Jeong YH, Park Y, Park KS, Yun SE, Park JR, Hwang SJ, Koh EH, Kwak CH, Hwang JY, Kim S. Platelet inhibition by adjunctive cilostazol vs. high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. JACC Cardiovasc Interv 2011; 4: 381-91.
    • (2011) JACC Cardiovasc Interv , vol.4 , pp. 381-391
    • Kim, I.S.1    Jeong, Y.H.2    Park, Y.3    Park, K.S.4    Yun, S.E.5    Park, J.R.6    Hwang, S.J.7    Koh, E.H.8    Kwak, C.H.9    Hwang, J.Y.10    Kim, S.11
  • 96
    • 84877768701 scopus 로고    scopus 로고
    • First pharmacogenomic analysis using whole exome sequencing to identify novel genetic determinants of clopidogrel response variability: results of the Genotype Information and Functional Testing (GIFT) EXOME study
    • Price MJ, Carson AR, Murray SS, Phillips T, Janel L, Tisch R, Topol EJ, Levy S. First pharmacogenomic analysis using whole exome sequencing to identify novel genetic determinants of clopidogrel response variability: results of the Genotype Information and Functional Testing (GIFT) EXOME study. J Am Coll Cardiol 2012; 59: E9.
    • (2012) J Am Coll Cardiol , vol.59
    • Price, M.J.1    Carson, A.R.2    Murray, S.S.3    Phillips, T.4    Janel, L.5    Tisch, R.6    Topol, E.J.7    Levy, S.8
  • 97
    • 84862504147 scopus 로고    scopus 로고
    • Clopidogrel efficacy and cigarette smoking status
    • Gurbel PA, Nolin TD, Tantry US. Clopidogrel efficacy and cigarette smoking status. JAMA 2012; 307: 2495-6.
    • (2012) JAMA , vol.307 , pp. 2495-2496
    • Gurbel, P.A.1    Nolin, T.D.2    Tantry, U.S.3
  • 102
    • 84877013453 scopus 로고    scopus 로고
    • Platelet function testing and prediction of procedural bleeding risk
    • Grove EL, Hossain R, Storey RF. Platelet function testing and prediction of procedural bleeding risk. Thromb Haemost 2013; 109: 817-24.
    • (2013) Thromb Haemost , vol.109 , pp. 817-824
    • Grove, E.L.1    Hossain, R.2    Storey, R.F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.